Tribune News Service
New Delhi, August 7
World’s leading vaccine maker Serum Institute of India on Friday said it would produce up to 100 million Covid-19 vaccine doses for India and low- and middle-income countries as early as 2021.
The institute in a statement said it would price each dose of the vaccine for USD 3 which roughly translates into Indian Rupees 225.
SII issued the statement after entering into what it called a new landmark collaboration between the SII, GAVI (Global Alliance for Vaccines) and Bill and Melinda Gates Foundation.
SII to get $150 mn from Gates Foundation
Under the arrangement the Bill and Melinda Gates Goundation via its strategic investment fund will provide at-risk funding of USD 150 million to GAVI which will be used to support the SII to manufacture the potential vaccine candidates.
“Vaccines will be priced at maximum USD 3 per dose and made available to the 92 countries included in GAVI’s COVAX Advance Market Commitment,” Adar Poonawala-led SII said in a statement.
Pune based Serum Institute has partnered with Oxford University and British Swedish Pharma firm Astra Zeneca to mass produce the frontrunner COVID 19 vaccine Covishield which has entered phase 3 clinical trials in some countries after showing safety and immune response in phase 1 and 2 studies in the UK.
Indian Drug controller has also permitted SII to undertake phase 2 and 3 human trials on Covishield in India.
Permit peaceful protest at Burari ground | Tomar issues fres...
Pact with Russian Direct Investment Fund